FindMyKOL
Clinical trialNCT01161199RecruitingObservational

The Use of Leukapheresis to Support HIV Pathogenesis Studies

NCT01161199 is an observational study sponsored by University of California, San Francisco. As of 21 Nov 2026, it is recruiting participants. It studies HIV. The registry lists an enrollment of 100 participants at 1 site in 1 country. The registry lists a start date of 26 Oct 2010 and a primary completion date of 31 Jul 2033. One of its registered investigators has a FindMyKOL profile.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01161199
FieldValue
Registry IDNCT01161199
StatusRecruiting
Study typeObservational study
Lead sponsorUniversity of California, San Francisco
Enrollment100
Registered sites1
Countries1
ConditionsHIV
Start26 Oct 2010
Primary completion31 Jul 2033
Study completion31 Jul 2033
Last update posted1 May 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Despite the dramatic improvements that have resulted from combination antiretroviral treatment, long-term efficacy, toxicity, cost, and the requirements for life-long adherence remain as formidable challenges. Also, there is emerging consensus that persistent HIV-associated disease occurs during long-term highly active antiretroviral therapy (HAART). This disease may be due to either direct drug-toxicity and/or persistent viral replication/production and/or persistent HIV-associated inflammation. Hence, strategies aimed at achieving complete viral eradication may be needed in order to fully restore health among HIV infected individuals. Even if complete eradication proves impossible-as most believe to be the case-a less rigorous but still desirable outcome might be achieving durable control of virus in the absence of therapy. That a "functional" cure is possible is well illustrated by those rare individuals who are able to durably control replication competent virus in the absence of therapy ("elite" controllers). A more complete understanding of the relationship between inflammation and viral persistence is necessary before more rationale studies of HIV eradication can be designed. Also, a well validated high through-put virologic assay needs to be developed that can estimate the size of the latent reservoir. Since the level of replication competent virus in long-term treated patients (and in elite controllers) is very small (\< 1% of CD4 cells harbor HIV), large numbers of CD4+ T cells most be obtained from study participants in order to routinely isolate and quantify virus persistence.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States1 site, 1 recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 1 site, 1 recruitingCA1NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT01161199

Each answer restates registry values shown on this page.

What is NCT01161199?

NCT01161199 is an observational study sponsored by University of California, San Francisco. It studies HIV.

Is NCT01161199 recruiting?

As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT01161199?

The registry names Steven Deeks, MD (principal investigator, University of California, San Francisco) as the overall official.

Where does NCT01161199 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When is NCT01161199 expected to complete?

The registry lists a primary completion date of 31 Jul 2033 and a study completion date of 31 Jul 2033. The sponsor last updated the record on 1 May 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.